{
    "2018-04-19": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Eli Lilly's Blockbuster Resurrection Story Has Holes",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Blockbuster",
                        "Resurrection",
                        "Holes"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug",
                "features": {
                    "keywords": [
                        "Gilead",
                        "shares",
                        "drop",
                        "FDA",
                        "concerns",
                        "Eli Lilly",
                        "Incyte",
                        "drug"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-17",
                "original_text": "Eli Lilly, Incyte shares fall after FDA cites issues with rheumatoid arthritis drug",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Incyte",
                        "shares",
                        "fall",
                        "FDA",
                        "issues",
                        "rheumatoid",
                        "arthritis",
                        "drug"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-18",
                "original_text": "FDA staff cites safety issues for Lilly, Incyte's rheumatoid arthritis drug",
                "features": {
                    "keywords": [
                        "FDA",
                        "staff",
                        "safety",
                        "issues",
                        "Lilly",
                        "Incyte",
                        "rheumatoid",
                        "arthritis",
                        "drug"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-19",
                "original_text": "ANIP, CMD Get FDA Nod, BMY Seeks New Use For Opdivo, Eloxx On Watch",
                "features": {
                    "keywords": [
                        "ANIP",
                        "CMD",
                        "FDA",
                        "Nod",
                        "BMY",
                        "Opdivo",
                        "Eloxx",
                        "Watch"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}